SCHEMBL4158668

SCHEMBL4158668

Fc1ccc(C(=S)Nc2ccc(Br)cc2Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
MAPT P10636 2/20 0.45
MAPK1 P28482 1/20 0.45
ALOX12 P18054 3/20 0.43
HPGD P15428 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
CTSL P07711 2/20 0.41
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
GPR35 Q9HC97 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446351 0.83 HPGD (0.58) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL29574909 0.83 HPGD (0.58) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL4158650 0.81 HDAC1 (0.58) SMN1; SMN2MEN1KMT2AMAPTHPGD
SCHEMBL28568216 0.81 NPC1 (0.52) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL29827720 0.80 L3MBTL1 (0.53) MEN1KMT2AMAPK1HPGDNPC1
SCHEMBL22779174 0.78 POLB (0.48) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL28575497 0.73 L3MBTL1 (0.56) LMNAMEN1KMT2AMAPTALOX12
SCHEMBL14182211 0.72 NPC1 (0.45) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL5429910 0.71 RAB9A (0.55) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL28568657 0.71 HPGD (0.47) LMNASMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012134-A1 Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists CURTIS NEIL ROY 2009-01-08 US disclosed
EP-1866300-A1 ARYLSULFONYL BENZOFUSED HETEROCYCLES AS 5-HT2A ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-12-19 EP disclosed
WO-2006100519-A1 ARYLSULFONYL BENZOFUSED HETEROCYCLES AS 5-HT2A ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012134-A1 Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists HTR2A, HTR2C, HTR2B LMNA 3294/4885SMN1; SMN2 483/4885MEN1 2418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.